- Home
- HY vs BCYC Comparison
HY vs BCYC Comparison
Compare HY & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HY | BCYC |
|---|---|---|
| Founded | 1991 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.5M | 516.8M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | HY | BCYC |
|---|---|---|
| Price | $32.78 | $7.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $18.73 |
| AVG Volume (30 Days) | 174.0K | ★ 293.3K |
| Earning Date | 11-04-2025 | 10-30-2025 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $3,913,600,000.00 | $28,339,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $218.81 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.41 | $6.03 |
| 52 Week High | $57.89 | $21.14 |
Technical Indicators
Market Signals| Indicator | HY | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 52.73 | 52.04 |
| Support Level | $32.27 | $7.03 |
| Resistance Level | $34.82 | $7.65 |
| Average True Range (ATR) | 1.91 | 0.37 |
| MACD | 0.44 | 0.07 |
| Stochastic Oscillator | 43.67 | 48.60 |
Price Performance
Historical ComparisonAbout HY Hyster-Yale Materials Handling Inc.
Hyster Yale Inc designs, engineers, manufactures, sells and services a comprehensive line of lift trucks, attachments, aftermarket parts and technology solutions marketed globally under the Hyster and Yale brand names. The Company has five segments, which include three in the lift truck business as discussed below, as well as Bolzoni S.p.A. (Bolzoni) and Nuvera Fuel Cells, LLC (Nuvera). Majority of revenue is from Lift Trucks. geographically operates in America, EMEA, JAPIC, maximum revenue from America.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.